{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:41:31Z","timestamp":1776836491680,"version":"3.51.2"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Metabolic bone disease of prematurity (MBDP) remains a significant cause of morbidity in extremely premature newborns. In high-risk patients, suspected diagnosis and subsequent treatment modifications, with limitations in terms of sensitivity and specificity, rely on low phosphorus levels and\/or high levels of alkaline phosphatase (ALP). We investigated the potential of fibroblast growth factor-23 (FGF23) as an early marker for MBDP when measured at 3\u20134 weeks of life in at-risk patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-center prospective observational non-interventional study including preterm newborns of both sexes, with a gestational age of less than 32 weeks and\/or a birth weight of less than 1500\u00a0g. In the standard biochemical screening for MBDP performed between 3 and 4 weeks of life within a nutritional profile, the determination of FGF23 was included along with other clinical and metabolic studies. The study was conducted at Marqu\u00e9s de Valdecilla University Hospital in Santander, Spain, from April 2020 to March 2021. Participants provided informed consent. Biochemical analyses were conducted using various platforms, and follow-up evaluations were performed at the discretion of neonatologists. Patients at high risk for MBDP received modifications in treatment accordingly. The sample was descriptively analyzed, presenting measures of central tendency and dispersion for continuous variables, and absolute numbers\/percentages for categorical ones. Tests used included t-tests, Mann\u2012Whitney U tests, chi-square tests, logistic regressions, Pearson correlation, and ROC curve analysis (IBM SPSS Statistics version 19). Significance level: <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the study involving 25 at-risk premature newborns, it was found that 20% (<jats:italic>n<\/jats:italic>\u2009=\u20095) were diagnosed with MBDP. Three of these patients (60%) were identified as high-risk based on standard biochemical evaluation at 3\u20134 weeks of age, while the other two patients (40%) were diagnosed in subsequent weeks. However, in all 5 patients, measurement of FGF23 levels would allow for early identification and optimization of treatment before other markers become altered. Low levels of FGF23 at 3\u20134 weeks, even with normal phosphorus and ALP levels, indicate the need for modifications in nutritional supplementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MBDP remains a significant concern in extremely premature newborns. Current diagnostic methods rely on limited biochemical markers. Early detection of low FGF23 levels enables timely interventions, potentially averting demineralization.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-024-04897-7","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:05:13Z","timestamp":1719882313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5519-8072","authenticated-orcid":false,"given":"Sandra","family":"Llorente-Pelayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Docio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-7643","authenticated-orcid":false,"given":"Bernardo A.","family":"Lav\u00edn-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-3284","authenticated-orcid":false,"given":"Mar\u00eda T.","family":"Garc\u00eda-Unzueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-9973","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-5540","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Cabero-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-241X","authenticated-orcid":false,"given":"Domingo","family":"Gonz\u00e1lez-Lamu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"issue":"1","key":"4897_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1824-7288-35-20","volume":"35","author":"V Bozzetti","year":"2009","unstructured":"Bozzetti V, Tagliabue P. Metabolic bone disease in preterm newborn: an update on nutritional issues. Ital J Pediatr. 2009;35(1):20.","journal-title":"Ital J Pediatr"},{"issue":"4","key":"4897_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4274\/jcrpe.galenos.2019.2019.0091","volume":"12","author":"S Chacham","year":"2020","unstructured":"Chacham S, Pasi R, Chegondi M, Ahmad N, Mohanty SB. Metabolic bone disease in premature neonates: an unmet challenge. J Clin Res Pediatr Endocrinol. 2020;12(4):332\u20139.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"4897_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev.nu.14.070194.001125","volume":"14","author":"FR Greer","year":"1994","unstructured":"Greer FR. Osteopenia of prematurity. Annu Rev Nutr. 1994;14:169\u201385.","journal-title":"Annu Rev Nutr"},{"key":"4897_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000342680","volume":"106","author":"C Pieltain","year":"2013","unstructured":"Pieltain C, de Halleux V, Senterre T, Rigo J. Prematurity and bone health. World Rev Nutr Diet. 2013;106:181\u20138.","journal-title":"World Rev Nutr Diet"},{"key":"4897_CR5","doi-asserted-by":"crossref","unstructured":"Takada M, Shimada M, Hosono S, Tauchi M, Minato M, Takahashi S, Okuni M, Takeuchi S. Trace elements and mineral requirements for very low birth weight infants in rickets of prematurity. Early Hum Dev. 1992;29(1\u20133):333\u20138.","DOI":"10.1016\/0378-3782(92)90188-M"},{"issue":"4","key":"4897_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/07853899608999080","volume":"28","author":"MC Backstr\u00f6m","year":"1996","unstructured":"Backstr\u00f6m MC, Kuusela AL, M\u00e4ki R. Metabolic bone disease of prematurity. Ann Med. 1996;28(4):275\u201382.","journal-title":"Ann Med"},{"issue":"3","key":"4897_CR7","first-page":"85","volume":"1","author":"SE Rustico","year":"2014","unstructured":"Rustico SE, Calabria AC, Garber SJ. Metabolic bone disease of prematurity. J Clin Transl Endocrinol. 2014;1(3):85\u201391.","journal-title":"J Clin Transl Endocrinol"},{"key":"4897_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fped.2019.00143","volume":"7","author":"MF Faienza","year":"2019","unstructured":"Faienza MF, D\u2019Amato E, Natale MP, Grano M, Chiarito M, Brunetti G, D\u2019Amato G. Metabolic bone disease of prematurity: diagnosis and management. Front Pediatr. 2019;7:143.","journal-title":"Front Pediatr"},{"key":"4897_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.earlhumdev.2017.06.010","volume":"112","author":"S Ukarapong","year":"2017","unstructured":"Ukarapong S, Venkatarayappa SKB, Navarrete C, Berkovitz G. Risk factors for metabolic bone disease of prematurity. Early Hum Dev. 2017;112:29\u201334.","journal-title":"Early Hum Dev"},{"issue":"12","key":"4897_CR10","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3346\/jkms.2012.27.12.1552","volume":"27","author":"SM Lee","year":"2012","unstructured":"Lee SM, Namgung R, Park MS, Eun HS, Park KI, Lee C. High incidence of rickets in extremely low birth weight infants with severe parenteral nutrition-associated cholestasis and bronchopulmonary dysplasia. J Korean Med Sci. 2012;27(12):1552\u20135.","journal-title":"J Korean Med Sci"},{"key":"4897_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/nu8120764","volume":"8","author":"V Christmann","year":"2016","unstructured":"Christmann V, Gradussen CJ, K\u00f6rnmann MN, Roeleveld N, van Goudoever JB, van Heijst AF. Changes in biochemical parameters of the calciumphosphorus homeostasis in relation to nutritional intake in very-low-birthweight infants. Nutrients. 2016;8:764.","journal-title":"Nutrients"},{"key":"4897_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/jpc.13813","volume":"54","author":"LK Chin","year":"2017","unstructured":"Chin LK, Doan J, Teoh YS, Stewart A, Forrest P, Simm PJ. Outcomes of standardized approach to metabolic bone disease of prematurity. J Padiatr Child Health. 2017;54:665\u201370.","journal-title":"J Padiatr Child Health"},{"key":"4897_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1891\/0730-0832.35.2.95","volume":"35","author":"KA Stalnaker","year":"2016","unstructured":"Stalnaker KA, Poskey GA. Osteopenia of prematurity: does physical activity improve bone mineralization in preterm infants? Neonatal Netw. 2016;35:95\u2013104.","journal-title":"Neonatal Netw"},{"key":"4897_CR14","first-page":"1106","volume":"5","author":"SYR Lee","year":"2017","unstructured":"Lee SYR. Prevention of metabolic bone disease of prematurity by optimizing calcium and phosphate contents in parenteral nutrition for premature infants. J Hum Nutr Food Sci. 2017;5:1106.","journal-title":"J Hum Nutr Food Sci"},{"key":"4897_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1651-2227.2007.00721.x","volume":"97","author":"CM Harrison","year":"2008","unstructured":"Harrison CM, Johnson K, McKechnie E. Osteopenia of prematurity: a national survey and review of practice. Acta Paediatr. 2008;97:407\u201313.","journal-title":"Acta Paediatr"},{"issue":"5","key":"4897_CR16","doi-asserted-by":"publisher","first-page":"e1676","DOI":"10.1542\/peds.2013-0420","volume":"131","author":"SA Abrams","year":"2013","unstructured":"Abrams SA, Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics. 2013;131(5):e1676\u201383.","journal-title":"Pediatrics"},{"issue":"1","key":"4897_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MPG.0b013e3181adaee0","volume":"50","author":"C Agostoni","year":"2010","unstructured":"Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, Domell\u00f6f M, Embleton ND, Fusch C, Genzel-Boroviczeny O, Goulet O, Kalhan SC, Kolacek S, Koletzko B, Lapillonne A, Mihatsch W, Moreno L, Neu J, Poindexter B, Puntis J, Putet G, Rigo J, Riskin A, Salle B, Sauer P, Shamir R, Szajewska H, Thureen P, Turck D, van Goudoever JB, Ziegler EE, ESPGHAN Committee on Nutrition. Enteral nutrient supply for preterm infants: commentary from the European Society of Pediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2010;50(1):85\u201391.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"4897_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0148607113487216","volume":"37","author":"D Nehra","year":"2013","unstructured":"Nehra D, Carlson SJ, Fallon EM, Kalish B, Potemkin AK, Gura KM, Simpser E, Compher C, Puder M. American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN J Parenter Enter Nutr. 2013;37(5):570\u201398.","journal-title":"JPEN J Parenter Enter Nutr"},{"issue":"5","key":"4897_CR19","doi-asserted-by":"publisher","first-page":"F560","DOI":"10.1136\/archdischild-2018-316330","volume":"104","author":"A Chinoy","year":"2019","unstructured":"Chinoy A, Mughal MZ, Padidela R. Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. Arch Dis Child Fetal Neonatal Ed. 2019;104(5):F560\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"4897_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/01202412-198909030-00012","volume":"9","author":"WW Koo","year":"1989","unstructured":"Koo WW, Sherman R, Succop P, Krug-Wispe S, Tsang RC, Steichen JJ, Crawford AH, Oestreich AE. Fractures and rickets in very low birth weight infants: conservative management and outcome. J Pediatr Orthop. 1989;9:326\u201330.","journal-title":"J Pediatr Orthop"},{"key":"4897_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/adc.64.7_Spec_No.902","volume":"64","author":"A Lucas","year":"1989","unstructured":"Lucas A, Brooke OG, Baker BA, et al. High alkaline phosphatase activity and growth in preterm neonates. Arch Dis Child. 1989;64:902\u201320.","journal-title":"Arch Dis Child"},{"key":"4897_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1067\/mpd.2000.108953","volume":"137","author":"MS Fewtrell","year":"2000","unstructured":"Fewtrell MS, Cole TJ, Bishop NJ, et al. Neonatal factors predicting childhood height in preterm infants: evidence for a persisting effect of early metabolic bone disease? J Pediatr. 2000;137:668\u201373.","journal-title":"J Pediatr"},{"issue":"2","key":"4897_CR23","first-page":"184","volume":"27","author":"J Rigo","year":"1998","unstructured":"Rigo J, Nyamugabo K, Picaud JC, Gerard P, Pieltain C, De Curtis M. Reference values of body composition obtained by dual energy X-ray absorptiometry in preterm and term neonates. J Pediatr Gastroenterol Nutr. 1998;27(2):184\u201390.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"4897_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jpeds.2013.10.089","volume":"164","author":"J Figueras-Aloy","year":"2014","unstructured":"Figueras-Aloy J, \u00c1lvarez-Dom\u00ednguez E, P\u00e9rez-Fern\u00e1ndez JM, Moretones-Su\u00f1ol G, Vidal-Sicart S, Botet-Mussons F. Metabolic bone disease and bone mineral density in very preterm infants. J Pediatr. 2014;164(3):499\u2013504.","journal-title":"J Pediatr"},{"issue":"3","key":"4897_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/jp.2011.82","volume":"32","author":"B Rack","year":"2012","unstructured":"Rack B, Lochm\u00fcller EM, Janni W, Lipowsky G, Engelsberger I, Friese K, et al. Ultrasound for the assessment of bone quality in preterm and term infants. J Perinatol. 2012;32(3):218\u201326.","journal-title":"J Perinatol"},{"issue":"2","key":"4897_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MPG.0b013e3181f8b295","volume":"52","author":"L Pereira-da-Silva","year":"2011","unstructured":"Pereira-da-Silva L, Costa A, Pereira L, Filipe A, Virella D, Leal E, et al. Early high calcium and phosphorus intake by parenteral nutrition prevents short-term bone strength decline in preterm infants. J Pediatr Gastroenterol Nutr. 2011;52(2):203\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"4897_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5662\/wjm.v5.i3.115","volume":"5","author":"MU Rehman","year":"2015","unstructured":"Rehman MU, Narchi H. Metabolic bone disease in the preterm infant: current state and future directions. World J Methodol. 2015;5(3):115\u201321.","journal-title":"World J Methodol"},{"issue":"1","key":"4897_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1651-2227.2003.tb00473.x","volume":"92","author":"M Catache","year":"2003","unstructured":"Catache M, Leone CR. Role of plasma and urinary calcium and phosphorus measurements in early detection of phosphorus deficiency in very low birthweight infants. Acta Paediatr. 2003;92(1):76\u201380.","journal-title":"Acta Paediatr"},{"issue":"7","key":"4897_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1651-2227.2000.tb00395.x","volume":"89","author":"MC Backstr\u00f6m","year":"2000","unstructured":"Backstr\u00f6m MC, Kouri T, Kuusela AL, Siev\u00e4nen H, Koivisto AM, Ikonen RS, et al. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Paediatr. 2000;89(7):867\u201373.","journal-title":"Acta Paediatr"},{"issue":"3","key":"4897_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1440-1754.2010.01901.x","volume":"47","author":"YL Hung","year":"2011","unstructured":"Hung YL, Chen PC, Jeng SF, Hsieh CJ, Peng SS, Yen RF, et al. Serial measurements of serum alkaline phosphatase for early prediction of osteopaenia in preterm infants. J Paediatr Child Health. 2011;47(3):134\u20139.","journal-title":"J Paediatr Child Health"},{"key":"4897_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1651-2227.2009.01506.x","volume":"99","author":"C Tsakalidis","year":"2010","unstructured":"Tsakalidis C, Dokos C, Tragiannidis A, Rallis D, Nikolaidis N. Gestational age, body weight and bone metabolism markers in premature infants: a single institution experience of Northern Greece. Acta Paediatr. 2010;99:99.","journal-title":"Acta Paediatr"},{"issue":"1","key":"4897_CR32","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1111\/jpc.12052","volume":"49","author":"A Moreira","year":"2013","unstructured":"Moreira A, February M, Geary C. Parathyroid hormone levels in neonates with suspected osteopenia. J Paediatr Child Health. 2013;49(1):E12\u20136.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"4897_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Min Res. 2004;19(3):429\u201335.","journal-title":"J Bone Min Res"},{"issue":"5","key":"4897_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2169\/internalmedicine.47.0730","volume":"47","author":"S Fukumoto","year":"2008","unstructured":"Fukumoto S. Physiological regulation and disorders of phosphate metabolism\u2013pivotal role of fibroblast growth factor 23. Intern Med. 2008;47(5):337\u201343.","journal-title":"Intern Med"},{"issue":"1","key":"4897_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jbmr.2606","volume":"31","author":"SK Murali","year":"2016","unstructured":"Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG. FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner. J Bone Min Res. 2016;31(1):129\u201342.","journal-title":"J Bone Min Res"},{"issue":"4","key":"4897_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/01.mnh.0000232885.81142.83","volume":"15","author":"M Kuro-o","year":"2006","unstructured":"Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate\/calcium metabolism. Curr Opin Nephrol Hypertens. 2006;15(4):437\u201341.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9929","key":"4897_CR37","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(13)61650-5","volume":"383","author":"CJ Elder","year":"2014","unstructured":"Elder CJ, Bishop NJ. Rickets. Lancet. 2014;383(9929):1665\u201376.","journal-title":"Rickets Lancet"},{"key":"4897_CR38","doi-asserted-by":"publisher","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-8. https:\/\/doi.org\/10.1002\/jbmr.340. Epub 2011 May 2. Erratum in: J Bone Miner Res. 2015;30(2):394.","DOI":"10.1002\/jbmr.340"},{"issue":"1","key":"4897_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Min Metab. 2012;30(1):1\u20139.","journal-title":"J Bone Min Metab"},{"issue":"1","key":"4897_CR40","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41598-017-03210-0","volume":"7","author":"K Yang","year":"2017","unstructured":"Yang K, Peretz-Soroka H, Wu J, Zhu L, Cui X, Zhang M, Rigatto C, Liu Y, Lin F. Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices. Sci Rep. 2017;7(1):3100.","journal-title":"Sci Rep"},{"issue":"1","key":"4897_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MED.0b013e328334f041","volume":"17","author":"DM Mitchell","year":"2010","unstructured":"Mitchell DM, J\u00fcppner H. Regulation of calcium homeostasis and bone metabolism in the fetus and neonate. Curr Opin Endocrinol Diabetes Obes. 2010;17(1):25\u201330.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"4897_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","volume":"314","author":"T Shimada","year":"2004","unstructured":"Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314(2):409\u201314.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4897_CR43","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/emmm.201303716","volume":"6","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014;6(6):744\u201359.","journal-title":"EMBO Mol Med"},{"key":"4897_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2431-9-47","volume":"9","author":"SM Mitchell","year":"2009","unstructured":"Mitchell SM, Rogers SP, Hicks PD, Hawthorne KM, Parker BR, Abrams SA. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr. 2009;9:47.","journal-title":"BMC Pediatr"},{"key":"4897_CR45","doi-asserted-by":"crossref","unstructured":"Grover M, Ashraf AP, Bowden SA, Calabria A, Diaz-Thomas A, Krishnan S, Miller JL, Robinson ME, DiMeglio LA. Invited mini review metabolic bone disease of prematurity: overview and practice recommendations. Horm Res Paediatr. 2024. Epub ahead of print. PMID: 38211570.","DOI":"10.1159\/000536228"},{"key":"4897_CR46","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1651-2227.2012.02626.x","volume":"101","author":"F Visser","year":"2012","unstructured":"Visser F, Sprij AJ, Brus F. The validity of biochemical markers in metabolic bone disease in preterm infants: a systematic review. Acta Paediatr. 2012;101:562\u20138.","journal-title":"Acta Paediatr"},{"issue":"12","key":"4897_CR47","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.3390\/nu12123854","volume":"12","author":"S Llorente-Pelayo","year":"2020","unstructured":"Llorente-Pelayo S, Docio P, Lavin-Gomez B, Garcia-Unzueta MT, De las Cuevas I, De la Rubia L, Cabero-Perez MJ, Gonz\u00e1lez-Lamu\u00f1o D. Modified serum ALP values and timing of apparition of Knee Epiphyseal Ossification Centers in Preterm infants with Cholestasis and risk of concomitant metabolic bone disease of Prematurity. Nutrients. 2020;12(12):3854.","journal-title":"Nutrients"},{"issue":"8","key":"4897_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1177\/0148607113499590","volume":"38","author":"S Viswanathan","year":"2014","unstructured":"Viswanathan S, Khasawneh W, McNelis K, Dykstra C, Amstadt R, Super DM, Groh-Wargo S, Kumar D. Metabolic bone disease: a continued challenge in extremely low birth weight infants. JPEN J Parenter Enter Nutr. 2014;38(8):982\u201390.","journal-title":"JPEN J Parenter Enter Nutr"},{"issue":"8","key":"4897_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1440-1754.2011.02019.x","volume":"47","author":"A Lothe","year":"2011","unstructured":"Lothe A, Sinn J, Stone M. Metabolic bone disease of prematurity and secondary hyperparathyroidism. J Paediatr Child Health. 2011;47(8):550\u20133.","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"4897_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205(2):385\u201390.","journal-title":"Atherosclerosis"},{"issue":"4","key":"4897_CR51","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1359\/jbmr.090831","volume":"25","author":"J Bacchetta","year":"2010","unstructured":"Bacchetta J, Boutroy S, Vilayphiou N, Juillard L, Guebre-Egziabher F, Rognant N, Sornay-Rendu E, Szulc P, Laville M, Delmas PD, Fouque D, Chapurlat R. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Min Res. 2010;25(4):849\u201357.","journal-title":"J Bone Min Res"},{"issue":"11","key":"4897_CR52","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00467-010-1565-3","volume":"25","author":"J Silver","year":"2010","unstructured":"Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol. 2010;25(11):2241\u20135.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"4897_CR53","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97(9):3357\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"4897_CR54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737\u201347.","journal-title":"Kidney Int"},{"issue":"9","key":"4897_CR55","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21(9):1427\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"4897_CR56","doi-asserted-by":"publisher","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","volume":"103S","author":"J Bacchetta","year":"2020","unstructured":"Bacchetta J, Bardet C, Pri\u00e9 D. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism. 2020;103S:153865.","journal-title":"Metabolism"},{"issue":"11","key":"4897_CR57","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00467-004-1574-1","volume":"19","author":"N Aladangady","year":"2004","unstructured":"Aladangady N, Coen PG, White MP, Rae MD, Beattie TJ. Urinary excretion of calcium and phosphate in preterm infants. Pediatr Nephrol. 2004;19(11):1225\u201331.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"4897_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1056\/NEJM199301213280304","volume":"328","author":"DS Rao","year":"1993","unstructured":"Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328(3):171\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"4897_CR59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrneph.2014.49","volume":"10","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268\u201378.","journal-title":"Nat Rev Nephrol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-04897-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:06:11Z","timestamp":1719882371000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-04897-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4897"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-04897-7","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the IRB (Comit\u00e9 de Investigaci\u00f3n con Medicamentos de Cantabria; reference 2019.294) and the Ethical Committee of the authors\u2019 hospital (CEIC-C: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica de Cantabria, project number CSI20\/09). Informed consent was obtained from all participants (parents or guardians) included in the study, in accordance with the criteria of the Ley de Investigaci\u00f3n Biom\u00e9dica 14\/2007.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}